Table 3 Characteristics of the patients with final fructosamine below the median value and of the patients with final fructosamine above the median value

Gender (M/F)

27/2

19/9

0.039

Age (yrs)

59 ± 10

59 ± 8

NS

Diabetes duration (yrs)

7 ± 7

9 ± 8

NS

History of previous CHD

8 (26 %)

7 (26 %)

NS

Tobacco smoking n(%)

10 (34 %)

8 (29 %)

NS

BMI (kg/m²)

31.0 ± 4.5

28.6 ± 3.6

0.048

Type of ACS n(%):

NS

- Anterior MI

12 (41.4 %)

8 (28.6 %)

- Inferior MI

16 (55.2 %)

18 (64.2 %)

- Lateral MI

1 (3.4 %)

1 (3.6 %)

- Unstable angina

0 (0 %)

1 (3.6 %)

Antidiabetic treatment at inclusion n(%):

NS

• Metformin

12 (41 %)

8 (29 %)

• Sulfonylurea or glinide

14 (48 %)

12 (43 %)

NS

• Acarbose

0 (0 %)

2 (7 %)

NS

• dpp4 inhibitor

1 (3 %)

2 (7 %)

NS

• Pioglitazone

1 (3 %)

1 (4 %)

NS

• Insulin

15 (52 %)

17 (61 %)

NS

Cardiovascular drugs n(%):

NS

• Statin

27 (93 %)

27 (96 %)

• ACE/inhibitor/ARB

28 (96 %)

24 (86 %)

NS

• Beta-blocker

25 (86 %)

23 (82 %)

NS

• Antiplatelet agents

29 (100 %)

28 (100 %)

NS

Baseline HbA1c (%)

7.9 ± 1.1

8.8 ± 1.4

0.015

Baseline fructosamine (μmol/l)

253 ± 40

297 ± 51

0.0001

Baseline VO2 peak (ml/kg/min)

17.1 ± 4.1

17.1 ± 4.7

NS

Baseline ventilatory threshold (ml/kg/min)

12.4 ± 3.2

12.4 ± 4.8

NS

Final (End-CR) fasting glucose (mg/dl)

119 ± 21

152 ± 32

0.005

Final (End-CR) HbA1c (%)

6.8 ± 0.9

7.9 ± 1.0

<0.0001

Final (End-CR) fructosamine (μmol/l)

213 ± 17

274 ± 29

<0.0001

Gain in VO2 peak (ml/kg/min)

3.5 ± 2.4

1.7 ± 2.4

0.014

Gain in ventilatory threshold (ml/kg/min)

2.7 ± 2.5

1.2 ± 1.9

0.040

CR responders n (%)

19 (66 %)

10 (36 %)

0.011

Patients on insulin during CR

22 (76 %)

25 (89 %)

NS

Mean insulin dose in insulin-treated patients (UI/day)

38 ± 24

46 ± 30

NS